Skip to main content
. Author manuscript; available in PMC: 2014 Oct 24.
Published in final edited form as: Leuk Lymphoma. 2013 Jan 28;54(9):1965–1974. doi: 10.3109/10428194.2012.755177

Figure 3.

Figure 3

Proportion of specimens with dysplasia according to treatment group [lenalidomide and dexamethasone (LD) alone, LD followed by autologous stem cell transplant (LD/ASCT) and bendamustine, lenalidomide and dexamethasone (BLD)] and time point. “n” represents the number of specimens that were evaluated at each time point. One specimen (*) with MDS at follow-up in the LD alone group had severe dyserythropoiesis and dysmegakaryopoiesis, but the dyserythropoiesis and dysmegakaryopoiesis in all other specimens was mild.